Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Bragnum Invest with their acquisition of SkySparc
Mandate

Vinge has advised Bragnum Invest with their acquisition of SkySparc

July 08, 2019 M&A

Vinge has advised Bragnum Invest with their acquisition of SkySparc, an independent solutions provider trusted by banks, central banks, Fortune 100 corporate treasuries and asset managers and offers complementary software, outsourced support and a wide range of financial and technical consulting services.

The core team consisted of Christina Kokko, project leaders Hedvig Ekdahl and Christina Odengran, Ulrich Ziche, Lisa Ullman, Sarah Berger, Agnes Perbo, Christopher Widström, Ilze Lukins and Victoria Owetz.

Existing SkySparc owners and staff will remain significant shareholders in the company.
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025